Press "Enter" to skip to content

Umoja Biopharma Announces Resignation of Board Chair Clay B. Siegall

  • Resignation effective immediately
  • CEO Scharenberg assumes the role of interim Board Chair

SEATTLE, May 11, 2022 (GLOBE NEWSWIRE) — Umoja Biopharma, Inc. announced today Clay B. Siegall, Ph.D. agreed to the Company’s request to resign from Umoja’s board of directors, effective immediately.

Andy Scharenberg, M.D., co-founder and Chief Executive Officer of Umoja said, “We do not expect Dr. Siegall’s absence from the Board to impact day-to-day activities as we continue to carry out the important work of creating curative treatments for solid tumors and blood cancers.”

Scharenberg assumes the role of interim Board Chair.

About Umoja Biopharma, Inc. 
Umoja Biopharma, Inc., is developing treatments for solid tumors and hematologic cancers that reprogram the patient’s immune system in vivo. Our technology platforms are designed to work synergistically as part of a therapeutic regimen that can be delivered to any patient, with any tumor, at any time. Based on pioneering work performed at Seattle Children’s Research Institute and Purdue University, Umoja’s approach is powered by novel cellular immunotherapy technologies including the VivoVec in vivo delivery platform, the RACR/CAR in vivo cell expansion/control platform, and the TumorTag targeting platform. Umoja believes its approach can broaden access to advanced immunotherapies to give more patients the hope of lasting remission. To learn more, visit http://umoja-biopharma.com/. 

Cautionary Note Regarding Forward-Looking Statements 
This press release contains forward-looking statements about Umoja Biopharma, Inc. (the “Company,” “we,” “us,” or “our”). The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason. 

Media Contact:
Darren Opland, Ph.D.
LifeSci Communications
darren@lifescicomms.com

Primary Logo

This post was originally published on this site

Be First to Comment

Leave a Reply

Your email address will not be published.